Peptide Therapeutics In Allergy Deal With SB
Hot on the heels of the intellectual property transfer deal it reachedwith Medeva (Marketletter February 3), UK-based Peptide Therapeutics has signed a strategic alliance with SmithKline Beecham, which it says will enable it to continue R&D on its allergy vaccine portfolio, the lead product of which has successfully completed a Phase IIa clinical trial.
The announcement of the collaboration sent Peptide's share price up 40 pence to 369 pence on February 10, and boosted the UK biotechnology sector generally (see pages 8 and 9).
Under the terms of the deal, SB acquires exclusive worldwide rights to market products arising from the alliance. SB also gains an option to license Peptide's tolerizing peptide to prevent hay fever.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze